Title |
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
|
---|---|
Published in |
BMC Health Services Research, September 2014
|
DOI | 10.1186/1472-6963-14-372 |
Pubmed ID | |
Authors |
Hideko Yamauchi, Chizuko Nakagawa, Shinji Yamashige, Hiroyuki Takei, Hiroshi Yagata, Atsushi Yoshida, Naoki Hayashi, John Hornberger, Tiffany Yu, Calvin Chao, Carl Yoshizawa, Seigo Nakamura |
Abstract |
Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available. The objective of this study was to evaluate the cost-effectiveness of the 21-gene assay for the guidance of adjuvant chemotherapy decisions in estrogen-receptor-positive, lymph-node-negative, early-stage breast cancer patients, from the Japanese societal perspective. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 63 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 16% |
Student > Master | 9 | 14% |
Other | 7 | 11% |
Student > Ph. D. Student | 6 | 10% |
Student > Postgraduate | 5 | 8% |
Other | 9 | 14% |
Unknown | 17 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 33% |
Economics, Econometrics and Finance | 5 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Nursing and Health Professions | 3 | 5% |
Other | 7 | 11% |
Unknown | 19 | 30% |